https://www.gov.uk/government/groups/uk-national-screening-committee-uk-nsc<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-02-14T17:38:39.303Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Breast Cancer: Screening"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of risk-stratified screening for breast cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4662", "label" : {"_value" : "Biography information for Ruth George"}
}
, "tablingMemberConstituency" : {"_value" : "High Peak"}
, "tablingMemberPrinted" : [{"_value" : "Ruth George"}
], "uin" : "219575"}
, {"_about" : "http://data.parliament.uk/resources/1058874", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1058874/answer", "answerText" : {"_value" : "My Rt. hon. Friend the Secretary of State for Health and Social Care has commissioned Baroness Dido Harding Chair of NHS Improvement, working closely with Sir David Behan, Chair of Health Education England, to lead a number of programmes to engage with key National Health Service interests to develop a detailed workforce implementation plan.<\/p>
<\/p>
This programme of work will consider detailed proposals to grow the workforce, including consideration of the additional staff and skills required to deliver round the clock high quality care. Baroness Harding and Sir David Behan will present initial recommendations to the Department in spring 2019. A final workforce implementation plan will follow later in the year, taking into account the outcomes of the Spending Review.<\/p>
<\/p>
Universities consistently continue to recruit students onto undergraduate diagnostic radiography university courses in England, with acceptances onto courses increasing every year since 2014. The latest NHS Digital data shows that as at October 2018 there are 3,084 more full time equivalent diagnostic radiographers in the NHS than there were in May 2010.<\/p>
<\/p>
Diagnostic radiographer education and training and recruitment in Wales, Northern Ireland and Scotland is a matter for the devolved governments in each nation.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-02-14T17:46:54.503Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Radiology: Recruitment"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the forthcoming NHS workforce implementation plan will include a plan to increase the numbers of NHS diagnostic radiographers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4662", "label" : {"_value" : "Biography information for Ruth George"}
}
, "tablingMemberConstituency" : {"_value" : "High Peak"}
, "tablingMemberPrinted" : [{"_value" : "Ruth George"}
], "uin" : "219576"}
, {"_about" : "http://data.parliament.uk/resources/1046081", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1046081/answer", "answerText" : {"_value" : "
The 2019 voluntary scheme for branded medicines pricing and access contains ambitions to improve patients\u2019 outcomes and the health gain from medicines spend by simplifying, streamlining and improving access, pricing and uptake arrangements for cost-effective medicines; and delivering faster adoption of the most clinically and cost-effective medicines.<\/p>
This will be supported by changes to the National Institute for Health and Care Excellence\u2019s value assessment of new products, availability of increased commercial flexibility, and support for the National Health Service to increase uptake where appropriate. Use of products, particularly those which provide greatest health gain for patients, will be monitored and reviewed through this scheme. NHS England is developing a cohesive commercial framework to support this.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-01-28", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-28T17:19:33.147Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-01-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps NHS England will take to encourage the uptake of innovative and cost-effective medicines as set out in the 2019 voluntary scheme for branded medicines pricing and access.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4662", "label" : {"_value" : "Biography information for Ruth George"}
}
, "tablingMemberConstituency" : {"_value" : "High Peak"}
, "tablingMemberPrinted" : [{"_value" : "Ruth George"}
], "uin" : "211348"}
, {"_about" : "http://data.parliament.uk/resources/1043706", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1043706/answer", "answerText" : {"_value" : "
In November 2018, my Rt. hon. Friend the Secretary of State for Health and Social Care, met with Roche to discuss life sciences, and briefly discussed the negotiations between Roche and NHS England on ocrelizumab. Similarly, the former Parliamentary Under-Secretary of State for Health (Lord O\u2019Shaughnessy) met with Roche in December 2018. Both Ministers encouraged the on-going negotiations and agreed that these negotiations needed to continue in order to ensure the best conclusion for both parties, and patients that suffer from primary progressive multiple sclerosis. Those discussions are rightly for NHS England and Roche and it would not be appropriate for Ministers to intervene.<\/p>
<\/p>
The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of ocrelizumab for the treatment of primary progressive multiple sclerosis. NHS England is in discussions with Roche, the manufacturer of ocrelizumab, to seek to agree a commercial agreement that might enable NICE to recommend use of the drug.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-01-23", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "210046"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-23T16:22:30.1Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-01-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Ocrelizumab"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what the status is of negotiations between Roche and NHS England on access to ocrelizumab for people with primary progressive MS on the NHS; and if he will take steps to help the two parties reach an agreement to deliver access to that drug.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4662", "label" : {"_value" : "Biography information for Ruth George"}
}
, "tablingMemberConstituency" : {"_value" : "High Peak"}
, "tablingMemberPrinted" : [{"_value" : "Ruth George"}
], "uin" : "210045"}
, {"_about" : "http://data.parliament.uk/resources/1043707", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1043707/answer", "answerText" : {"_value" : "
In November 2018, my Rt. hon. Friend the Secretary of State for Health and Social Care, met with Roche to discuss life sciences, and briefly discussed the negotiations between Roche and NHS England on ocrelizumab. Similarly, the former Parliamentary Under-Secretary of State for Health (Lord O\u2019Shaughnessy) met with Roche in December 2018. Both Ministers encouraged the on-going negotiations and agreed that these negotiations needed to continue in order to ensure the best conclusion for both parties, and patients that suffer from primary progressive multiple sclerosis. Those discussions are rightly for NHS England and Roche and it would not be appropriate for Ministers to intervene.<\/p>
<\/p>
The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of ocrelizumab for the treatment of primary progressive multiple sclerosis. NHS England is in discussions with Roche, the manufacturer of ocrelizumab, to seek to agree a commercial agreement that might enable NICE to recommend use of the drug.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-01-23", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "210045"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-23T16:22:30.147Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-01-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Ocrelizumab"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) Roche and (b) NHS England on introducing a managed access scheme for ocrelizumab to made available for people living with primary progressive MS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4662", "label" : {"_value" : "Biography information for Ruth George"}
}
, "tablingMemberConstituency" : {"_value" : "High Peak"}
, "tablingMemberPrinted" : [{"_value" : "Ruth George"}
], "uin" : "210046"}
, {"_about" : "http://data.parliament.uk/resources/1035107", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1035107/answer", "answerText" : {"_value" : "
No, as an ageing society, we need to reach a longer-term sustainable settlement for social care. The Social Care Green Paper remains a priority and the Government has committed to publishing at the earliest opportunity.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-01-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-09T12:30:38.41Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-01-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Social Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the Government\u2019s preparations for the UK leaving the EU potentially with no deal are expected to delay the publication of the Social Care Green Paper.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4662", "label" : {"_value" : "Biography information for Ruth George"}
}
, "tablingMemberConstituency" : {"_value" : "High Peak"}
, "tablingMemberPrinted" : [{"_value" : "Ruth George"}
], "uin" : "205416"}
, {"_about" : "http://data.parliament.uk/resources/1035108", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1035108/answer", "answerText" : {"_value" : "
The Social Care Green Paper remains a priority for this Government. The Department is working hard to publish a Green Paper setting out proposals for reform at the earliest opportunity.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-01-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-09T12:29:34.607Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-01-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Social Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps the Department is taking to ensure that the Social Care Green Paper is published at the earliest opportunity.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4662", "label" : {"_value" : "Biography information for Ruth George"}
}
, "tablingMemberConstituency" : {"_value" : "High Peak"}
, "tablingMemberPrinted" : [{"_value" : "Ruth George"}
], "uin" : "205417"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&tablingMemberPrinted.=Ruth+George&_page=1&min-AnswerDate=2018-11-12&max-questionFirstAnswered.=2019-07-08T13%3A00%3A06.227Z", "page" : 0, "startIndex" : 1, "totalResults" : 13, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}